LIVIVO - Search results -

Search results

Result 1 - 10 of total 25

Search options

Article ; Online: The role of CEUS in the management of biloma.

Marinato, Valentina / Phillips, Alice / Giuliano, Leonardo / Cascella, Tommaso / Greco, Giorgio / Lanocita, Rodolfo

2024

Abstract: Background: A biloma refers to an abnormal, well-defined accumulation of bile outside the biliary tree within the abdomen, which can be either intra- or extra-hepatic in nature. It can result from traumatic or iatrogenic causes, leading to a disruption ... ...

Abstract	Background: A biloma refers to an abnormal, well-defined accumulation of bile outside the biliary tree within the abdomen, which can be either intra- or extra-hepatic in nature. It can result from traumatic or iatrogenic causes, leading to a disruption in the biliary system. Without prompt diagnosis and appropriate management, it can result in significant morbidity and mortality. While magnetic resonance cholangiopancreatography (MRCP) is the typical diagnostic method, there are instances where it may not provide conclusive results. Case presentation: We present the case of a 72-year-old woman who underwent an hepatic resection of the seventh segment after recurrence of hepatocellular carcinoma (HCC). During the ultrasound (US) follow-up, she developed a peri-hepatic collection which proved to be a biloma continuously refurnished by the biliary tree. Neither the MRCP nor the percutaneous transhepatic cholangiography (PTC) were able to clearly detect the exact site of the bile leak. While awaiting the Endoscopic Retrograde Cholangio-Pancreatography (ERCP), a Contrast-Enhanced Ultrasound (CEUS) was conducted administering the contrast agent directly through the percutaneous drainage catheter placed in the biloma. This revealed the presence of contrast flow from the collection to a peripheral right bile duct, confirming the intra-hepatic leak communication. Conclusions: This case demonstrates that Contrast-Enhanced Ultrasound (CEUS) presents a straightforward, secure, and precise approach to detect biliary leakage responsible for the formation of a biloma. Additionally, the adoption of CEUS offers the dual benefit of minimizing radiation exposure for the patient and obviating the requirement for anesthesia. In summary, CEUS emerges as a compelling alternative to conventional diagnostic methods for effectively managing a biloma.
Language	English
Publishing date	2024-02-08
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2365426-0
ISSN	1876-7931 ; 1971-3495
ISSN (online)	1876-7931
ISSN	1971-3495
DOI	10.1007/s40477-023-00849-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article: Hepatocellular Carcinoma Recurrence After Liver Transplantation.

Gabutti, Alejandro / Bhoori, Sherrie / Cascella, Tommaso / Bongini, Marco

Oncology (Williston Park, N.Y.)

2020 Volume 34, Issue 3

Abstract: Key Points • Recurrent HCC after OLT management is challenging and notoriously difficult. • High oncologic-risk patient identification and close follow-up are essential. • Recurrences diagnosed within the first 2 years after OLT can be classified as ... ...

Abstract	Key Points • Recurrent HCC after OLT management is challenging and notoriously difficult. • High oncologic-risk patient identification and close follow-up are essential. • Recurrences diagnosed within the first 2 years after OLT can be classified as early-onset and are associated with poor prognosis. • Surgical resection should be the first curative attempt when it is technically feasible. • TACE in patients who have undergone OLT appears to be effective and safe. • Sorafenib can be used as systemic therapy in cases with multi-organ recurrence; newer therapies are emerging. • The benefit of immunosuppression with an mTOR inhibitor has not been established. • In the posttransplant setting, a combination treatment approach is warranted.
MeSH term(s)	Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/surgery ; Combined Modality Therapy ; Female ; Hepatitis C/pathology ; Humans ; Liver Neoplasms/etiology ; Liver Neoplasms/pathology ; Liver Neoplasms/surgery ; Liver Transplantation ; Middle Aged ; Neoplasm Recurrence, Local/etiology ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Risk Factors ; Treatment Outcome
Language	English
Publishing date	2020-03-19
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1067950-9
ISSN	0890-9091
ISSN	0890-9091
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3168: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 372: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A "blood theft" after liver transplantation: the role of interventional radiology in the management and treatment of splenic artery steal syndrome.

Riva, Federica / Garanzini, Enrico M / Cascella, Tommaso / Marchianò, Alfonso / Spreafico, Carlo

Journal of radiology case reports

2022 Volume 16, Issue 8, Page(s) 1–7

Abstract: Splenic artery steal syndrome is a rare complication after liver transplant. It could lead to rapidly evolving major issues such as ischemic cholangiopathy and acute graft failure. Although the pathophysiology is not yet well understood, if diagnosed in ... ...

Abstract	Splenic artery steal syndrome is a rare complication after liver transplant. It could lead to rapidly evolving major issues such as ischemic cholangiopathy and acute graft failure. Although the pathophysiology is not yet well understood, if diagnosed in time it could be easily managed with interventional radiology treatments. We present a case of a 47-year-old man presented to our institute with radiological findings typical for multifocal hepatocellular carcinoma in a cirrhotic liver. After therapy he underwent transplant. Some days after surgery he developed signs of acute liver failure. Steal syndrome was suspected by laboratory tests and radiology exams. The syndrome was confirmed by angiography and treated. The graft was saved, and the patient is still alive and free of disease. The purpose of this paper is to explain the importance of radiology exams in the diagnosis of splenic steal syndrome, explain its pathogenesis and describe the interventional management of this complication.
MeSH term(s)	Humans ; Liver ; Liver Transplantation/adverse effects ; Male ; Middle Aged ; Radiology, Interventional ; Splenic Artery/diagnostic imaging ; Splenic Artery/surgery ; Syndrome ; Theft
Language	English
Publishing date	2022-08-01
Publishing country	United States
Document type	Case Reports
ZDB-ID	2586384-8
ISSN	1943-0922 ; 1943-0922
ISSN (online)	1943-0922
ISSN	1943-0922
DOI	10.3941/jrcr.v16i8.4391
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Penile Metastases From Renal Cell Carcinoma: Pre and Postcontrast Sonographic Findings.

Gitto, Salvatore / Vaiani, Marta / Cascella, Tommaso / Lanocita, Rodolfo

Ultrasound quarterly

2018 Volume 34, Issue 4, Page(s) 285–287

Abstract: The prostate and bladder are the most common primary cancer sites for penile metastases. Here, we describe an unusual case of metastases from renal cell carcinoma to the penis discovered 1 month after nephrectomy in a 60-year-old man. The diagnosis was ... ...

Abstract	The prostate and bladder are the most common primary cancer sites for penile metastases. Here, we describe an unusual case of metastases from renal cell carcinoma to the penis discovered 1 month after nephrectomy in a 60-year-old man. The diagnosis was achieved using B-mode and contrast-enhanced ultrasound.
MeSH term(s)	Carcinoma, Renal Cell/pathology ; Contrast Media ; Diagnosis, Differential ; Humans ; Image Enhancement/methods ; Male ; Middle Aged ; Penile Neoplasms/diagnostic imaging ; Penile Neoplasms/secondary ; Penis/diagnostic imaging ; Ultrasonography/methods
Chemical Substances	Contrast Media
Language	English
Publishing date	2018-03-06
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	645107-x
ISSN	1536-0253 ; 0894-8771
ISSN (online)	1536-0253
ISSN	0894-8771
DOI	10.1097/RUQ.0000000000000347
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2485: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Surveillance or Dynamic Sentinel Lymph-Node Biopsy in Low-Risk Clinically N0 Penile Squamous Cell Carcinoma: Single-Institution Real World Data.

Nazzani, Sebastiano / Catanzaro, Mario / Bruniera, Martina / Torelli, Tullio / Macchi, Alberto / Stagni, Silvia / Tesone, Antonio / Silvani, Carlo / Ceccato, Tommaso / Bernasconi, Valentina / Lanocita, Rodolfo / Cascella, Tommaso / Claps, Melanie / Giannatempo, Patrizia / Zimatore, Matteo / Cattaneo, Laura / Biasoni, Davide / Montanari, Emanuele / Nicolai, Nicola

Clinical genitourinary cancer

2024 Volume 22, Issue 2, Page(s) 544–548

Abstract: Introduction: Surveillance is the standard management in low-risk cN0 penile squamous cell carcinoma (peSCC) patients. However, no previous analysis focused on early and long-term outcomes of these patients. We report on main oncological outcomes of a ... ...

Abstract	Introduction: Surveillance is the standard management in low-risk cN0 penile squamous cell carcinoma (peSCC) patients. However, no previous analysis focused on early and long-term outcomes of these patients. We report on main oncological outcomes of a large series of low-risk cN0 peSCC patients. Patients and methods: Between 1980 and 2017 included, 93 evaluable consecutive low-risk (ie, pT1a G1 cN0M0) peSCC patients underwent primary tumor surgery and either observation (74) or dynamic sentinel node biopsy (DSNB) (19) following a clinical diagnosis of T1 in 66 (71%), T2 in 15 (16.1%) and Tx in 12 (12.9%) patients, respectively. The statistical significance of differences in medians and proportions was tested with the Kruskal-Wallis and chi-square tests. Kaplan-Meier plots illustrated 5-year inguinal relapse (IR)-free survival rates. Results: Median age was 60 years (IQR: 50-69 years). Median follow-up was 92 months (IQR 54-133 months). Surveillance was more frequently adopted in clinical (c)T1 than in cT2 tumors (79.7% vs. 36.8%). None of 19 patients who had DSNB had nodal metastasis. Overall, 7 (7.5%) out of 93 pT1aG1cN0 peSCC patients had IR after a median interval of 9 months. Of note, 1 patient only relapsed after 12 months of surveillance. After stratification according to IR, relapses occurred more frequently in younger patients (59 vs. 64 years, P < .001). The 5-year IR-free survival rates for the entire cohort was 92% (95% Confidence interval [CI] 87-98%). Conclusions: Observation is a safe and effective management for low-risk peSCC patients. Younger patients may be offered a mini-invasive staging as an alternative.
MeSH term(s)	Male ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Sentinel Lymph Node Biopsy ; Penile Neoplasms/pathology ; Carcinoma, Squamous Cell/pathology ; Neoplasm Staging
Language	English
Publishing date	2024-01-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	2225121-2
ISSN	1938-0682 ; 1558-7673
ISSN (online)	1938-0682
ISSN	1558-7673
DOI	10.1016/j.clgc.2024.01.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Contrast-Enhanced Ultrasound-Guided Percutaneous Biopsy of the Peritoneum: A Series of 3 Cases.

Panarisi, Nicol Antonina Rita / Cascella, Tommaso / Morosi, Carlo / Greco, Francesca Gabriella / Marchianò, Alfonso / Lanocita, Rodolfo

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine

2020 Volume 39, Issue 7, Page(s) 1441–1446

Abstract: In the presence of peritoneal disease, patients often should undergo biopsy of the peritoneum for acquiring a specific pathologic diagnosis. Ultrasound is ideal for guiding peritoneal biopsy, although in some situations, it can be technically challenging. ...

Abstract	In the presence of peritoneal disease, patients often should undergo biopsy of the peritoneum for acquiring a specific pathologic diagnosis. Ultrasound is ideal for guiding peritoneal biopsy, although in some situations, it can be technically challenging. The addition of a contrast agent can improve the visualization of lesions and adjacent organs, providing radiologists increased confidence. A contrast agent can identify perfused areas within the target lesion, improving diagnostic accuracy. We present 3 cases of contrast-enhanced ultrasound-guided peritoneal biopsy. In all cases, we gained a specific diagnosis. No immediate or delayed complications occurred. Contrast-enhanced ultrasound-guided biopsy proved to be a simple, safe, and accurate diagnostic method.
MeSH term(s)	Humans ; Image-Guided Biopsy ; Peritoneal Diseases/diagnostic imaging ; Peritoneum/diagnostic imaging ; Sensitivity and Specificity ; Ultrasonography ; Ultrasonography, Interventional
Language	English
Publishing date	2020-01-27
Publishing country	England
Document type	Case Reports
ZDB-ID	604829-8
ISSN	1550-9613 ; 0278-4297
ISSN (online)	1550-9613
ISSN	0278-4297
DOI	10.1002/jum.15230
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1793: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 495: Show issues

Order via subito

Details ▾

Article ; Online: Bilateral inguinal lymph-node dissection vs. unilateral inguinal lymph-node dissection and dynamic sentinel node biopsy in clinical N1 squamous cell carcinoma of the penis.

Nazzani, Sebastiano / Catanzaro, Mario / Biasoni, Davide / Maccauro, Marco / Stagni, Silvia / Torelli, Tullio / Macchi, Alberto / Bernasconi, Valentina / Taverna, Alessandra / Sessa, Dario / Lorenzoni, Alice / Piva, Luigi / Lanocita, Rodolfo / Cascella, Tommaso / Cattaneo, Laura / Montanari, Emanuele / Salvioni, Roberto / Nicolai, Nicola

Urologic oncology

2023 Volume 41, Issue 4, Page(s) 210.e1–210.e8

Abstract: Introduction: To evaluate the role of unilateral inguinal lymph-node dissection (ILND) plus contralateral dynamic sentinel node biopsy (DSNB) vs. bilateral ILND in clinical N1 (cN1) penile squamous cell carcinoma (peSCC) patients.: Material and ... ...

Abstract	Introduction: To evaluate the role of unilateral inguinal lymph-node dissection (ILND) plus contralateral dynamic sentinel node biopsy (DSNB) vs. bilateral ILND in clinical N1 (cN1) penile squamous cell carcinoma (peSCC) patients. Material and methods: Within our institutional database (1980-2020, included), we identified 61 consecutive cT1-4 cN1 cM0 patients with histological confirmed peSCC who underwent either unilateral ILND plus DSNB (26) or bilateral ILND (35). Results: Median age was 54 years (Interquartile range [IQR]: 48-60 years). Median follow-up was 68 months (IQR 21-105 months). Most patients had pT1 (23 %) or pT2 (54.1%), as well as G2 (47.5%) or G3 (23%) tumors, while lymphovascular invasion (LVI) was present in 67.1% of cases. Considering a cN1 and a cN0 groin, overall 57 out of 61 patients (93.5%) had nodal disease in the cN1 groin. Conversely, only 14 out of 61 patients (22.9%) had nodal disease in the cN0 groin. 5-year IR-free survival was 91% (Confidence interval [CI] 80%-100%) for bilateral ILND group and 88% (CI 73%-100%) for the ipsilateral ILND plus DSNB group (P-value 0.8). Conversely, 5-year CSS was 76% (CI 62%-92%) for bilateral ILND group and 78% (CI 63%-97%) for the ipsilateral ILND plus contralateral DSNB group (P-value 0.9). Conclusions: In patients with cN1 peSCC the risk of occult contralateral nodal disease is comparable to cN0 high risk peSCC and the gold standard, namely bilateral ILND, may be replaced by unilateral ILND and contralateral DSNB without affecting positive node detection, IRRs and CSS.
MeSH term(s)	Male ; Humans ; Middle Aged ; Sentinel Lymph Node Biopsy ; Lymph Node Excision ; Lymph Nodes/surgery ; Lymph Nodes/pathology ; Penis/pathology ; Penile Neoplasms/surgery ; Penile Neoplasms/pathology ; Carcinoma, Squamous Cell/surgery ; Carcinoma, Squamous Cell/pathology ; Neoplasm Staging
Language	English
Publishing date	2023-03-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	1336505-8
ISSN	1873-2496 ; 1078-1439
ISSN (online)	1873-2496
ISSN	1078-1439
DOI	10.1016/j.urolonc.2023.02.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4817: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Hepatocellular Carcinoma in Abernethy Malformation: A Rare Occurrence of Congenital Complete Portosystemic Shunt.

Virdis, Matteo / Monteleone, Michela / Sposito, Carlo / Cascella, Tommaso / Pellegrinelli, Alessandro / Mazzaferro, Vincenzo

Journal of vascular and interventional radiology : JVIR

2018 Volume 29, Issue 12, Page(s) 1775–1778

MeSH term(s)	Aged ; Angiography, Digital Subtraction ; Biopsy ; Carcinoma, Hepatocellular/diagnostic imaging ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/physiopathology ; Carcinoma, Hepatocellular/radiotherapy ; Computed Tomography Angiography ; Embolization, Therapeutic/methods ; Female ; Humans ; Liver Circulation ; Liver Neoplasms/diagnostic imaging ; Liver Neoplasms/etiology ; Liver Neoplasms/physiopathology ; Liver Neoplasms/radiotherapy ; Phlebography/methods ; Portal Vein/abnormalities ; Portal Vein/diagnostic imaging ; Portal Vein/physiopathology ; Radiopharmaceuticals/administration & dosage ; Single Photon Emission Computed Tomography Computed Tomography ; Treatment Outcome ; Vascular Malformations/complications ; Vascular Malformations/diagnostic imaging ; Vascular Malformations/physiopathology ; Yttrium Radioisotopes/administration & dosage
Chemical Substances	Radiopharmaceuticals ; Yttrium Radioisotopes ; Yttrium-90 (1K8M7UR6O1)
Language	English
Publishing date	2018-10-30
Publishing country	United States
Document type	Case Reports ; Letter
ZDB-ID	1137756-2
ISSN	1535-7732 ; 1051-0443
ISSN (online)	1535-7732
ISSN	1051-0443
DOI	10.1016/j.jvir.2018.07.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3720: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Radioembolization of Hepatocellular Carcinoma with

Romanò, Chiara / Mazzaglia, Stefania / Maccauro, Marco / Spreafico, Carlo / Gabutti, Alejandro / Maffi, Gabriele / Morosi, Carlo / Cascella, Tommaso / Mira, Marta / De Nile, Maria Chiara / Aliberti, Gianluca / Argiroffi, Giovanni / Fuoco, Valentina / Bhoori, Sherrie / Zanette, Consuelo / Marchianò, Alfonso / Seregni, Ettore / Mazzaferro, Vincenzo / Chiesa, Carlo

Cancers

2022 Volume 14, Issue 4

Abstract: In this confirmatory study, we tested if a calculation that included the non-uniformity of dose deposition through a voxel-based dosimetric ... ...

Abstract	In this confirmatory study, we tested if a calculation that included the non-uniformity of dose deposition through a voxel-based dosimetric variable
Language	English
Publishing date	2022-02-15
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14040959
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.

BMC cancer

2023 Volume 23, Issue 1, Page(s) 908

Abstract: Background: Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET pathogenesis, including c-MET and ... ...

Abstract	Background: Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET pathogenesis, including c-MET and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). LOLA is the first prospective phase II trial aiming to assess the safety and activity of cabozantinib combined with lanreotide in WD NETs of gastroenteropancreatic (GEP), thoracic and of unknown origin. Methods: This is a multicenter, open-label, double-cohort, non comparative, non-randomized, three-stage phase II trial. Eligible patients have to meet the following inclusion criteria: diagnosis of advanced or metastatic, progressive, non-functioning WD thoracic NETs, GEP-NETs or NETs of unknown origin with Ki67 ≥ 10%; positive 68 Ga-PET uptake or somatostatin receptor 2 immunohistochemical (IHC) stain; maximum 1 prior systemic regimen for metastatic disease. Two cohorts will be considered: pNETs and carcinoids (typical or atypical lung and thymus NETs, gastro-intestinal NETs or NETs of unknown origin). In stage I, the primary objective is to find the optimal dose of cabozantinib in combination with lanreotide and to evaluate the safety of the combination (percentage of patients experiencing grade 3-5 toxicities according to NCI-CTCAE version 5.0). Starting dose of cabozantinib is 60 mg/day continuously, plus lanreotide 120 mg every 28 days. In stage II and III, co-primary endpoints are safety and overall response rate (ORR) according to RECIST version 1.1. The uninteresting antitumor activity is fixed in ORR ≤ 5%. Secondary endpoints are progression-free survival and overall survival. Exploratory objectives include the assessment of c-MET, AXL and VEGFR2 IHC expression, to identify predictive or prognostic tissue biomarkers. Enrolment started in July 2020, with an expected trial duration of 42 months comprehensive of accrual, treatment and follow-up. Considering a drop-out rate of 5%, the maximum number of enrolled patients will be 69. Discussion: Supported by a solid rationale, the trial has the potential to generate milestone data about the synergistic effects of cabozantinib plus lanreotide in a group of NET patients with relatively aggressive disease and limited therapeutic options. Trial registration: LOLA is registered at ClinicalTrials.gov (NCT04427787) and EudraCT (2019-004506-10).
MeSH term(s)	Humans ; Neuroendocrine Tumors/drug therapy ; Prospective Studies ; Vascular Endothelial Growth Factor A ; Thoracic Neoplasms ; Multicenter Studies as Topic ; Clinical Trials, Phase II as Topic
Chemical Substances	lanreotide (0G3DE8943Y) ; cabozantinib (1C39JW444G) ; Vascular Endothelial Growth Factor A
Language	English
Publishing date	2023-09-26
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article
ZDB-ID	2041352-X
ISSN	1471-2407 ; 1471-2407
ISSN (online)	1471-2407
ISSN	1471-2407
DOI	10.1186/s12885-023-11287-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito